Treating eligible adult patients with relapsed/refractory CTCL

C-APROM/GB/ADCE/0396 | December 2025

Related content

PI Adcetris (brentuximab vedotin)

Expert-led podcast: Exploring sALCL case studies and the treatment landscape

Approx. 27 mins

Listen to Dr Matthew Wilson, Consultant Haematologist at the Beatson West of Scotland Cancer Centre, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss diverse clinical presentations of sALCL and their personal management strategies by exploring two real-world patient case studies.

podcast

PI Adcetris (brentuximab vedotin)

Expert-led podcast: Multidisciplinary management of CTCL

Approx. 22 mins

Listen to Professor Julia Scarisbrick, Consultant Dermatologist at University Hospital Birmingham NHS Foundation Trust, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss the multidisciplinary management of adult patients with CTCL. They explore the role of haematologists, dermatologists, oncologists and clinical nurse specialists in managing these patients.

podcast

PI Adcetris (brentuximab vedotin)

Expert-led podcast: Navigating the assessment and treatment of CTCL

Approx. 26 mins

Listen to clinical experts explore the heterogeneous nature of CTCL, defining the subtypes MF, pcALCL and SS. Professor Whittaker, Consultant Dermatologist at Guy’s and St.